Company intelligence / Profile preview
Gedea Biotech
Lund, Sweden
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
pHyph has shown rapid symptom relief and long-term effects in clinical studies for bacterial vaginosis. By day 7, 60-70% of patients report absence of fishy smell, and 80-90% experience noticeable symptom relief. The clinical cure rate is on par with antibiotics on the market, with a superior safety profile, lower recurrence rate, and without causing secondary VVC infections. At day 35, 100% of cured patients remain free from BV[1][4].
- Therapeutic areas
- Women's HealthInfectious Diseases
- Modalities
- Vaginal tablets
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Karolinska Institutet (research collaboration)
Beyond the preview
Go deeper on Gedea Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gedea Biotech.